News & media
NEWS

Our food evolves to better support the oral health of small dogs

2024/06/19 - Products

Vignette_corpo_HPM_S&T.jpgSmall dogs suffer up to five times more oral disease1 than other dogs. To nourish them while taking care of their oral health, our teams have reformulated our Veterinary HPM Small & Toy food. Launched in Europe in June, the new formula now includes a natural ingredient with proven efficacy against plaque, tartar, bleeding gums and bad breath.

Read more

Europe: experts meet to talk about canine mobility

2024/06/17 - Products

Vignette_corpo_symposium_movoflex.jpgIn June, 10 European veterinary experts in canine mobility met in Nice to share with our teams their experience and knowledge on canine mobility disorders.

Read more

Companion animals: first reproductive control guidelines presented!

2024/05/30 - Products

Vignette_corpo_webinar.jpgOn April 17, our teams, in collaboration with recognized experts, organized a webinar dedicated to the first WSAVA guidelines on reproductive control for dogs and cats. More than 6,000 veterinarians from around the world expressed interest in this important animal health topic.

Read more

Latin America: supporting good canine vaccination practices

2024/05/28 - Products

vignette_corpo_webinar_immuno.jpgMore than 3,500 veterinarians in South America registered for the webinar our teams organized last April. Our goal: to share the latest recommendations on canine vaccination from the World Small Animal Veterinary Association (WSAVA). 

Read more

Europe: our commitment to fight canine leishmaniosis continues

2024/04/19 - Products

Vignette_corpo_Leish.jpgFor more than 20 years, our teams have worked to combat this zoonotic disease that threatens the health of dogs and humans alike. In 2024, we continue to work to bring diagnostic, prevention and treatment solutions to veterinarians and dog owners in endemic areas. Our latest stop is France, which will host the Animal Leishmaniosis International Veterinary Event in Nice in April.

Read more

2024 first quarter consolidated sales

2024/04/16 - Financial public releases

Building on the momentum of the second half of 2023, strong first-quarter revenue growth of +10.8% at constant exchange rates

Read more

Virbac acquired Sasaeah, a leading animal health player in Japan.

2024/04/02 - Financial public releases

Sasaeah.jpgOn April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species.

Read more

Asia: our teams support growth in canine dermatology

2024/03/28 - Products

DAILYDERMA IN ASIA.jpgAs in other parts of the world, around 10%1 of dogs in Asia suffer from atopic dermatitis. Since 2022, our teams have been stepping up their efforts to develop our global DailyDerma program in the region. The goal? To better help Asian veterinarians optimize their dermatology practices and improve the management of skin diseases, especially complex atopic dermatitis. 

Read more

2023 Annual results

2024/03/19 - Financial public releases

●    Revenue up 4.9%, enabling market share gains despite difficulties in 2023

●    2023 operating profitability1 at an all-time high of 23.2% of revenue
     ○ Up 0.4 points compared to 2022 

●    Strong momentum expected in 2024
     ○  Expected revenue growth of 4% to 6% at constant exchange rates and scope
     ○  Operating profitability1 expected to rise by 0,5 point

 

Read more

Europe: new prevention solutions for swine farming

2024/03/07 - Products

Swine_vaccination.jpgOne year after the launch of Suigen Rota Coli, our teams in France and Germany are now offering a second vaccine for swine, Suigen APP 2,9,11. This new vaccine complements our solutions for the prevention of major swine diseases, helping farmers to better control the health of their farms.

Read more

Virbac to take a leading position in Japan through the acquisition of Sasaeah

2024/03/06 - Financial public releases

Sasaeah.jpgVirbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million.

Read more

Virbac: Olivier Charmeil co-opted by the board of directors

2024/01/24 - Career

Olivier_Charmeil_150x200.jpgVirbac announces the appointment of Olivier Charmeil as a new member of the board of directors with effect from December 21, 2023. He replaces Olivier Bohuon, permanent representative of OJB Conseil, within the board of directors and the appointments and compensation committee. 

Read more

Virbac shampoos for dogs and cats get a makeover!

2024/01/23 - Products

shampoos.jpgOur range of dermatological (AKI) and hygiene (Allerderm) shampoos has been redesigned to limit ecological impact and simplify use for pet owners. The new packaging is now made from recycled plastic, while the innovative formulations, which have been constantly improved over the last few decades, remain unchanged.

Read more

2023 fourth quarter consolidated sales

2024/01/17 - Financial public releases

Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%

Read more

Happy New Year 2024!

2024/01/08 - Press

Discover the video of Sébastien Huron's wishes to all Virbac teams worldwide.

Read more

Outlook 2023-2024

2023/12/19 - Financial public releases

Read more

Dog and cat nutrition: the beginnings of a new approach in China

2023/12/14 - Products

HPM_China.jpgAvailable in five major Chinese cities since last October, our Veterinary HPM® physiological foods are the only ones in the country to be distributed exclusively in veterinary clinics. This is a novel approach in the region, in line with our medical and scientific approach to animal nutrition. 

Read more

Pets: a step towards more reasoned pest control

2023/11/23 - Products

Vignette_corpo_Lets_do_it_smart.jpgBecause we are all part of the same ecosystem, parasite control is a necessity which must be carried out while preserving the delicate balance between the health of animals, humans and their environment. With “Let's do it smart”, we provide veterinarians with the tools they need to tailor the solution to the animal's specific needs, thus contributing to a more reasoned use of parasiticides. 

Read more

Companion animal vaccines: a state-of-the-art production line installed in France

2023/11/17 - Press

Savannah_Corpo.jpgA new filling line has been installed in Carros, marking the beginning of the transformation of our production system.

Read more

France: Virbac certified as an Authorized Economic Operator

2023/11/10 - Press

OEA-Vignette.jpgAt the end of October, the French Customs Department awarded our Group the status of Authorized Economic Operator (AEO): a European customs seal of approval, recognized on the international scene.

Read more

Virbac Uruguay celebrates its 10 years and builds a new factory

2023/11/03 - Press

Vignette_corpo_Uruguay (1).jpgOn October 17, Virbac Uruguay celebrated 10 years of commitment to animal health in Montevideo. On this occasion, the foundation stone for our new viral antigen plant was laid in the presence of the President of the Republic of Uruguay. 

Read more

Virbac acquired a majority stake in Globion, a leading Indian poultry vaccines specialist

2023/11/02 - Financial public releases

Acquistion_Virbac_octobre_300x200.jpgOn November 1, we successfully finalized the acquisition of a majority stake in Globion. This transaction will bolster our position of animal health leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines. 

Read more

2023 third quarter consolidated sales

2023/10/23 - Financial public releases

Revenue growth at the end of September at +2.8% at constant exchange rates and scope thanks to a strong activity rebound in the third quarter (+7.8% at constant exchange rates and scope).

Read more

USA: Virbac innovates for the treatment of Giardia duodenalis infections in dogs

2023/10/18 - Products

Eradia.jpgOn October 11, 2023, the U.S. Food and drug administration (FDA) approved our solution for the treatment of Giardia duodenalis infections in dogs.

Read more

Dog oral health: an effective solution against plaque and tartar

2023/10/13 - Products

Vignette_corpo_vetaquadent_study.jpgA study published in September 2023 has scientifically demonstrated that Vet Aquadent® FR3SH is an effective option to help maintain dogs' oral health after professional dental cleaning.

Read more

Virbac will enter the fast-growing poultry vaccines segment in India

2023/10/09 - Financial public releases

Acquistion_Virbac_octobre_300x200.jpgVirbac announces the signing of an agreement to acquire Globion, a leading Indian poultry vaccines specialist. This transaction will bolster our position of animal health market leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines.

Read more

2023 half year results

2023/09/28 - Financial public releases

Current operating income before R&D slightly improving throughout first half of 2023 in percentage of revenue

Read more

Nutrition: a new approach for aging cats

2023/09/07 - Products

vignette_site_corpo_HPM_K&J.jpegIn France and around the world, the medicalization of cats continues to progress, helping to increase their life expectancy. Two major pathologies affect these aging cats: chronic kidney disease and osteoarthritis. Specially adapted nutrition can help. That's why we're launching VETERINARY HPM® Kidney & Joint in Europe in September. This new nutrition program enables the combined and gradual management of chronic kidney disease and osteoarthritis, thus improving the animal's quality of life. 

Read more

Virbac launches a share buyback program

2023/08/22 - Financial public releases

Following the decision of the board of directors on June 19, 2023 and its approval by the shareholder’s meeting, we are going to buy back 100,000 of our own shares (less than 1.25% of the capital). Main objective: to decrease the company's share capital by canceling treasury shares purchased.

Read more

2023 half-year results: publication postponed to end of September

2023/08/22 - Financial public releases

At the end of August, with our priority systems fully restored and functional following the June cyberattack, we will be able to publish our mid-year results on September 28 with a two-week delay.

Read more